



● Scientific Program ●

(August 23, 2006)

Friday, September 8

5:00pm-8:00pm Registration

Saturday, September 9

7:30am-6:00pm Registration

10:00-4:00pm Live Surgery*

12:30-3:00 Lunch

5:00-7:00 Fluorescein Angiography & Surgical Case Conference*

8:00-11:00 Welcome Reception and Dinner*

Sunday, September 10

7:30am-5:00pm Registration

8:00-9:10 **Symposium I: Anti-Angiogenesis (Part 1)***

Presiding Officer: Susan B. Bressler

Chair: Ursula Schmidt-Erfurth

Moderator: Tom S. Chang

8:00-8:05 **Opening Remarks**

Julia Haller, Didier Ducournau, & Jean-Paul Amar

8:05-8:12 **Combined Efficacy of Intravitreal Ranibizumab in Two Phase III Studies of Choroidal Neovascularization Secondary to Age-related Macular Degeneration**

Anat Loewenstein

8:12-8:19 **Combined Safety of Intravitreal Ranibizumab in Two Phase III Studies of Choroidal Neovascularization Secondary to Age-Related Macular Degeneration**

Paolo Lanzetta

8:19-8:26 **Two-year Efficacy and Safety Results from the MARINA Study**

Ursula Schmidt-Erfurth

8:26-8:33 **Consistency of Effect of Ranibizumab at 2 doses on Contrast Sensitivity in 3 Phase III and IIIB Studies of Patients with CNV Secondary to AMD**

Jean-Francois Korobelnik

8:33-8:37 **Discussion**

8:37-8:44 **Intravitreal Ranibizumab (Lucentis™) plus Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration: FOCUS 2-year Results**

Andrew N. Antoszyk

8:44-8:51 **PIER: Year 1 Results of a Phase IIIB Study of Ranibizumab Efficacy and Safety in Choroidal Neovascularization due to Age-Related Macular Degeneration**

Prema Abraham

- 8:51-8:58 **Pier: Year 1 FA/OCT Results in a Study of Ranibizumab (Lucentis™) for Choroidal Neovascularization (CNV) due to Age-Related Macular Degeneration (AMD)**
William F. Mieler
- 8:58-9:05 **An OCT-Guided Variable-Dosing Regimen with Lucentis™ (Ranibizumab) in Neovascular AMD: One Year Results from the PrONTO Study**
Philip J. Rosenfeld
- 9:05-9:10 **Discussion**
- 9:10-9:15 **Introduction of Featured Guest Lecturer: Judah Folkman**
Presiding Officers: Didier Ducourneau, Julia A. Haller, and Eugene de Juan, Jr.
- 9:15-10:00 **Potential Future Advances in Ophthalmology from Research in Tumor Angiogenesis**
Judah Folkman
- 10:00-10:05 **Discussion**
- 10:05-10:40 Break/Exhibits/Poster Session (AMD/Anti-Angiogenesis) – Authors Present***
- 10:40 1:10 Symposium II: Anti-Angiogenesis (Part 2)***
Presiding Officer: Lawrence J. Singerman
Chair: David F. Williams
Moderators: Frank HJ Koch
- 10:40-10:47 **Open-label, Multicenter, Phase II Study Assessing the Safety and Efficacy of Same-day Verteporfin and Liquid Ranibizumab 0.5mg (PROTECT study)**
Sebastian Wolf
- 10:47-10:54 **Ranibizumab (Lucentis™) Vision-Specific Quality of Life Through 24 Months In Neovascular AMD Subjects In Marina: A Phase III Clinical Trial**
Tom S. Chang
- 10:54-11:01 **Vision-Specific Quality of Life at 12 Months In Predominantly Classic Neovascular AMD In Anchor: A Phase III Trial of Ranibizumab and Verteporfin PDT**
Neil M. Bressler
- 11:01-11:08 **The Value and Cost-Effectiveness of Interventions for Subfoveal Neovascular, Age-Related Macular Degeneration (ARMD)**
Melissa Brown
- 11:08-11:12 **Discussion**
- 11:12-11:16 **Intravitreally Injected Anti-VEGF Drugs Exert a Biological Effect in the Fellow Eye**
Tongalp H. Tezel
- 11:16-11:20 **Pharmacokinetics of Intravitreal Bevacizumab (Avastin)**
Sophie J. Bakri
- 11:20-11:24 **Vitreous Levels of Unbound Bevacizumab and Unbound Vascular Endothelial Growth Factors in Two Human Subjects**
Paul M. Beer
- 11:24-11:28 **Stability of Bevacizumab (Avastin) after Withdrawal into a Syringe and Refrigeration or Freezing**
Colin A. McCannel
- 11:28-11:31 **Discussion**
- 11:31-11:36 **Intravitreal Bevacizumab for the Treatment of Choroidal Neovascularization Secondary to Ocular Histoplasmosis and Multifocal Choroiditis**
Sundeep Dev
- 11:36-11:41 **Short-Term Outcomes in over 500 Intravitreal Bevacizumab Treatments for Retinal or Choroidal Vascular Disease at the New York Eye & Ear Infirmary**
Thomas O. Muldoon

- 11:41-11:46 **Intravitreal Bevacizumab as Isolated First Line Therapy In Patients with New Untreated Choroidal Neovascular Membranes**
Alay S. Banker
- 11:46-11:51 **Six-month Follow up on 50 Consecutive Patients with Intravitreal Bevacizumab Injections for Neovascular Age Related Macular Degeneration**
Samira Khan
- 11:51-11:55 **Discussion**
- 11:55-12:00pm **Primary Intravitreal Bevacizumab (Avastin) for the Treatment of CNV Secondary to AMD: Results of the Pan-American Collaborative Retina Study Group**
Jans Fromow-Guerra
- 12:00-12:05 **Intravitreal Bevacizumab (Avastin) for the Treatment of Neovascular Age-Related Macular Degeneration (AMD)**
Alessandro A. Castellarin
- 12:05-12:10 **Intravitreal Bevacizumab (Avastin™) for Primary Treatment of Neovascular AMD**
David F. Williams
- 12:10-12:15 **Intravitreal Bevacizumab (Avastin) Treatment of Choroidal Neovascularization Secondary to Age-Related Macular Degeneration**
Richard F. Spaide
- 12:15-12:18 **Discussion**
- 12:18-12:23 **Time to Recurrence of AMD-related CNV Leakage After a Single Initial Intravitreal Injection Bevacizumab (Avastin®): Implications for a Retreatment**
Edgar L. Thomas
- 12:23-12:28 **A FA/ICG Analysis of the Retinal/Choroidal Vasculature and Choroidal Neovascular Membrane Complex Six Months Following Intravitreal Avastin Injections**
Paul E. Tornambe
- 12:28-12:33 **Intravitreal Bevacizumab Compared with Photodynamic Therapy for Juxtafoveal Choroidal Neovascular Membranes in Age Related Macular Degeneration**
Derek L. Barker
- 12:33-12:38 **Combination Therapy for Wet Age-related Macular Degeneration Using Verteporfin Photodynamic Therapy and Intravitreal Bevacizumab**
Jose Dalma-Weiszhausz
- 12:38-12:41 **Discussion**
- 12:41-12:46 **Combined Photodynamic Therapy with Verteporfin and Intravitreal Bevacizumab for Choroidal Neovascularization in Age-Related Macular Degeneration.**
Gaurav K. Shah
- 12:46-12:51 **Combined Photodynamic Therapy with Verteporfin and Intravitreal Bevacizumab for Subfoveal Choroidal Neovascularization in AMD**
David M. Misch
- 12:51-12:56 **Combination Avastin and Reduced Fluence Photodynamic Therapy for Choroidal Neovascularization**
David Callanan
- 12:56-1:01 **Intravitreal Bevacizumab (Avastin) Enhanced Pegaptanib (Macugen) therapy for Choroidal Neovascularization in AMD: An Avastin Booster**
Michael J. Tolentino
- 1:01-1:06 **Vitrectomy in Triple Therapy for Choroidal Neovascularization**
Frank H.J. Koch
- 1:06-1:10 **Discussion**
- 1:10-2:40 Young Physicians Section' Lunch***
Crystal Apple Lecture: Controversies in the Management and Prevention of Endophthalmitis
Harry W. Flynn, Jr., MD

- 1:10-2:40** **Lunch/Exhibits***
- 2:40-4:15** **Symposium III: Anti-Angiogenesis (Part 3)***
 Presiding Officer: Paul E. Tornambe
 Chair: Anthony P. Adamis
 Moderator: Albert J. Augustin
- 2:40-2:47 **C.L.E.A.R – IT 1: A Phase I Safety, Tolerability, and Bioactivity Study of Intravitreal VEGFTrap in Patients with Neovascular AMD**
 Quan Dong Nguyen
- 2:47-2:54 **VEGF Small Interfering (si) RNA, for Treatment of Wet Age-Related Macular Degeneration (AMD)**
 Lawrence J. Singerman
- 2:54-3:00 **The Effects of Combined Inhibition of Platelet-Derived Growth Factor (PDGF)-B and VEGF-A Signaling in Murine Models of Ocular Neovascularization**
 Anthony P. Adamis
- 3:00- 3:06 **The Role of a Selective VEGF Blockade in Age-related Macular Degeneration (AMD)**
 Thomas R. Friberg
- 3:06-3:12 **Anecortave Acetate Clinical Update**
 Peter K. Kaiser
- 3:12- 3:16 **Discussion**
- 3:16-3:22 **Combined Intravitreal Triamcinolone with Photodynamic Therapy for the Treatment of Choroidal Neovascularization in Age-related Macular Degeneration**
 Catherine Favard
- 3:22-3:28 **The Effect of Kenalog as Adjunctive Treatment to Visudyne in Minimally Classic and Occult Neovascular AMD: A Prospective, Randomized Clinical Trial**
 Tom Sheidow
- 3:28-3:34 **Six-month Results of a Randomized, Double-Masked, Controlled Trial of Intravitreal Triamcinolone as an Adjunct to Photodynamic Therapy in Predominantly Classic Neovascular Age-related Macular Degeneration. The Canadian RETINA Study**
 David Maberley
- 3:34-3:40 **Large Case Series of Different Types of CNV after Combination Treatment (PDT with intravitreal Triamcinolone)**
 Albert J. Augustin
- 3:40-3:45 **Discussion**
- 3:45-4:15 **AMD-panel Discussion**
 Moderator: Philip J. Rosenfeld
 Panelists: Jans Fromow-Guerra, Anat Loewenstein, David Maberley, Ursula Schmidt-Erfurth, Gisele Soubrane, Richard F. Spaide

Evening Free

Monday, September 11

7:30am-4:30pm Registration

- 8:00-10:00** **Awards & Special Presentations***
 Presiding Officers: Julia A. Haller, Eugene de Juan, Jr. and George A. Williams
- 8:00-8:05 Introduction of Pyron Award Winner: Brooks W. McCuen, II
- 8:05-8:35 **Pyron Award Lecture: Evolving Concepts in Pharmacologic Vitreolysis**
 Brooks W. McCuen, II

- 8:35-8:40 Introduction of Founders Award Winner: Kirk H. Packo
- 8:40-9:10 **Founders Award Lecture: Vitrectomy Technology - Where We've Been. Where We Are. Where We Are Going**
Kirk H. Packo
- 9:10-9:20 **Pay for Performance: A True Quality Initiative or a Means of Cost Control**
William L. Rich, III
- 9:20-9:25 **American Retina Foundation**
Roy A. Levit
- 9:25-9:27 **Young Physicians Section's Crystal Apple Award Presentation**
- 9:27-9:30 **PAT Survey Award**
- 9:30-10:00 **ASRS Business Meeting**
- 10:00-10:40 Break/Exhibits/Poster Session (Imaging/Surgical Devices & Instrumentation/Pharmacology/Socioeconomics – Authors Present***
- 10:40-1:10pm Symposium IV: Imaging and AMD***
Presiding Officer: Giovanni Staurenghi
Chair: Claude R. Boscher
Moderator: Gregg T. Kokame
- 10:40-10:45 **Retinal Measurements with 3D-OCT**
Alexander C. Walsh
- 10:45-10:50 **SOCT "Copernicus" a New Diagnostic Tool in Retinology**
Jerzy Nawrocki
- 10:50-10:55 **Active Choroidal Neovascularization without Subretinal or Intraretinal Fluid on OCT Imaging**
G. Baker Hubbard
- 10:55-11:00 **Dualing OCT Modalities: Contrasting Retinal Features Revealed by a Dual Mode High Speed Ultrahigh Resolution Spectral and Temporal OCT/SLO Imager**
Richard B. Rosen
- 11:00-11:05 **Spectral Domain Optical Coherence Tomography Provides New Insight into the Extent of Macular Pathology in Age-Related Macular Degeneration**
Cynthia A. Toth
- 11:05-11:08 **Discussion**
- 11:08-11:13 **AMD, Hypertension and Potential Cardiovascular Risks with Intravitreal Avastin Injection**
Claude R. Boscher
- 11:13-11:17 **Humanistic Burden and Health Resource Utilization in Neovascular Age-Related Macular Degeneration (AMD) Patients from Five Countries**
Gisele Soubrane
- 11:17-11:22 **Comparison of Comorbid Conditions Between Wet AMD Patients and a Control Cohort in the Medicare Population**
Gergana Zlateva
- 11:22-11:27 **Myocardial Infarction and Cerebrovascular Accident Rates in Patients with Neovascular Age-Related Macular Degeneration in a Healthcare Claims Database**
Emily S. West
- 11:27-11:32 **Annual Rates of Cardiovascular Events in Medicare Neovascular Age-Related Macular Degeneration Patients**
Tsoncho Ianchulev
- 11:32-11:36 **Discussion**
- 11:36-11:41 **Long Term Results of the Age-Related Eye Disease Study (AREDS)**
Emily Y. Chew

- 11:41-11:46 **Vitamin Usage Patterns in the Prevention of Advanced Age-Related Macular Degeneration in a Tertiary Care Population**
Susan B. Bressler
- 11:46-11:51 **Discussion**
- 11:51-11:56 **Effect of Initial Visual Acuity on Visual Loss in Untreated AMD Eyes with Subfoveal Neovascularization**
Lucian V. Del Priore
- 11:56-12:01pm **Incident Choroidal Neovascular Lesions in the Fellow Eyes of Participants with Unilateral Neovascular AMD during the Submacular Surgery Trials**
Sharon D. Solomon
- 12:01-12:06 **Quantitative OCT Sub-Analysis in Neovascular Age-related Macular Degeneration**
Srinivas Sadda
- 12:06-12:11 **Treatment of Retinal Angiomatous Proliferation Lesions Associated with Pigment Epithelial Detachment with Focal Pulsed Laser**
Robert P. Murphy
- 12:11-12:15 **Results of a 1 Year Study of Feeder Vessel Therapy (FVT) in Age Related Macular Degeneration**
Giovanni Staurenghi
- 12:15-12:18 **Discussion**
- 12:18-12:23 **How many days after onset is it too late to evacuate submacular hemorrhage secondary to AMD?**
Keye L. Wong
- 12:23-12:28 **Pneumatic Displacement of Submacular Hemorrhage- A Case Series**
Wilson J. Heriot
- 12:28-12:33 **Comparison of Submacular Surgery and Natural History for the Treatment of Large Submacular Hemorrhages from Macular Degeneration**
John T. Thompson
- 12:33-12:38 **Recurrent Choroidal Neovascularization after Macular Translocation Surgery with 360-degree Peripheral Retinectomy**
Claxton A. Baer (Winner 2006 B&L Retina Fellows' Forum Research Award)
- 12:38-12:42 **Subretinal Surgery for Peripapillary Subretinal Neovascular Membranes (SRNVMS)**
Gregg T. Kokame
- 12:42-12:45 **Discussion**
- 12:45-12:50 **Prolonged Choroidal Hypofluorescence following Verteporfin PDT Combined with Intravitreal Triamcinolone Acetate Injection for Age-related CNVM**
Jeffrey K. Luttrull
- 12:50-12:55 **Increased Visual Acuity in Fellow Affected Eyes of Subjects Undergoing Therapy with Intravenous EVIZON™ (Squalamine lactate) for Exudative AMD**
Michael Gast
- 12:55-1:00 **Two-year Phase II/III Results (IMT002) of a Visual Prosthesis for Treatment of Central Vision Loss due to End-Stage Macular Degeneration**
Henry L. Hudson
- 1:00-1:10 **Discussion**
- 1:10-2:10 Lunch/Exhibits***
- 2:10-4:15 Symposium V: Surgical Devices and Instrumentation (Part 1)***
Presiding Officer: Michael T. Trese
Chair: Tarek S. Hassan
Moderator: Claus Eckardt
- 2:10-2:15 **Evaluation of the Artificial Silicon Retina™ Device for the Treatment of Vision Loss from Retinitis Pigmentosa**
John S. Pollack

- 2:15-2:20 **Chronic Retinal Chip Implant in Blind Patients with Retinitis Pigmentosa**
Gisbert Richard
- 2:20-2:25 **Results from a Chronically Implanted 16-Channel Epiretinal Prosthesis in Blind Subjects**
Robert J. Greenberg
- 2:25-2:28 **Discussion**
- 2:28-2:33 **Shedding More Light on Endoillumination**
David R. Chow
- 2:33-2:38 **Initial Clinical Experience with a Patterned Scanning Laser (PASCAL) for the Treatment of Retinal Diseases**
Julia A. Haller
- 2:38-2:43 **Results of Ophthalmic Surgical Training Using a High-fidelity Surgical Simulator Coupled with a Curriculum Based on Task Breakdown and Analysis**
Michael Grodin
- 2:43-2:48 **Cannulation of the Suprachoroidal Space: Drug Delivery and Pharmacokinetics of Triamcinolone Acetonide and Bevacizumab**
Timothy W. Olsen
- 2:48-2:53 **Enzymatic Alteration of Vitreous Cavity Oxygen Levels**
Michael T. Trese
- 2:53-2:56 **Discussion**
- 2:56-3:01 **20 Gauge Sutureless Transconjunctival Vitrectomy**
Daniel G. Polya
- 3:01-3:06 **Transconjunctival 20-G Sutureless Vitrectomy**
Mikael Sebag
- 3:06-3:09 **Discussion**
- 3:09-3:14 **25 Gauge Vitrectomy: Outcomes and Complications**
Carl D. Regillo
- 3:14-3:19 **Complications of 25-gauge Vitrectomy Surgery**
Robert A. Mittra
- 3:19-3:24 **A Head-to-Head Intraoperative Clinical Comparison of Flow Rates: Electric vs. Pneumatic 25-gauge High-Speed Vitreous Cutters**
Tarek S. Hassan
- 3:24-3:27 **Discussion**
- 3:27-3:31 **23-gauge Vitrectomy as an Effective and Safe Alternative for Sutureless Vitreous Surgery**
Keith A. Warren
- 3:31-3:35 **23-Gauge Vitrectomy in 100 Eyes: Short-Term Visual Outcomes and Complications**
Harinderjit Singh
- 3:35-3:40 **Further Experience with 23-gauge Transconjunctival Vitrectomy**
Claus Eckardt
- 3:40-3:44 **23g Sutureless Vitrectomy: When and Why?**
Zoran Tomic
- 3:44-3:49 **A New 23 Gauge Vitrectomy System**
George A. Williams
- 3:49-3:54 **New Devices for Vitreoretinal Surgery**
Carl C. Awh
- 3:54-3:57 **Discussion**

- 3:57-4:15 **Surgical Devices and Instrumentation Panel Discussion**
Moderator: Carl C. Awh
Panelists: David R. Chow, Claus Eckhardt, Stanislao Rizzo, Robert Wendel
- 4:15-5:00 **EVRS Business Meeting***
- 7:20-8:00pm **Coach transportation to Palm Beach Casino***
- 7:30-1:00am **Casablanca Night at Palm Beach Casino***

Tuesday, September 12

7:30am-4:30pm Registration

- 8:00-8:55 **Symposium VI: Surgical Devices and Instrumentation (Part 2)***
Presiding Officer: Suber S. Huang
Chair: Steve T. Charles
Moderator: Oswaldo M. Brasil, Sr.
- 8:00-8:05 **Comparison Of Wound Leakage between Straight and Tunnel Scleral Incisions after 25 Gauge Vitrectomy**
Luiz Hagemann
- 8:05-8:10 **The Integrity of Wound Closure after 23 versus 25 gauge Sutureless Vitrectomy**
Oswaldo Moura Brasil, Jr.
- 8:10-8:15 **Untoward Surgical Events in 25 Gauge Vitreoretinal Surgery**
Saad A. Shaikh
- 8:15-8:20 **Comparison of Visual Recovery Time in Patients Undergoing 20g and 25 gauge Vitreous Surgery**
Suber S. Huang
- 8:20-8:25 **Discussion**
- 8:25-8:30 **Vitreous Dynamics: The New Solid Development Concept. Vitreous Flow Analysis in 20, 23 and 25 Gauge Cutters**
Octaviano Magalhaes
- 8:30-8:35 **Fluid Dynamics among Different 25-gauge Systems: Principles for Use in Vitreoretinal Surgery**
Michel E. Farah
- 8:35-8:40 **Improved understanding of TSV-25g Vitrectomy system: Qualitative High Speed Video Analysis Of Vitreous Movement Around Aperture of Vitreous Cutters**
Mark S. Humayun
- 8:40-8:45 **Interface Vitrectomy**
Steve T. Charles
- 8:45-8:50 **Passive Removal of Silicone Oil with 25-Gauge Transconjunctival Sutureless Vitrectomy Instruments**
Ziya Kapran
- 8:50-8:55 **Discussion**
- 8:55-10:00 **Symposium VII: Retinal Vascular Disease and Oncology***
Presiding Officer: Suber S. Huang
Chair: Steve T. Charles
Moderator: Oswaldo M. Brasil, Sr.
- 8:55-9:00 **Reversal of Ischemic Central Retinal Vein Occlusion: A Novel Technique of Multiple Retinal Vein Decompression and Chorioretinal Venous Anastomosis**
Calvin A. Grant
- 9:00-9:05 **Radial Optic Neurotomy Plus Intravitreal Triamcinolone with and without Internal Limiting Membrane Peeling for Central Retinal Vein Occlusion**
Jose Garcia-Arumi

- 9:05-9:10 **Safety Profile of Various Steroids on Retinal Cells In Vitro**
Baruch D. Kuppermann
- 9:10-9:14 **Discussion**
- 9:14-9:19 **Pegaptanib Sodium for the Treatment of Macular Edema Following Central Retinal Vein Occlusion**
John Wells
- 9:19-9:24 **Short Term Visual and Anatomic Outcomes Following Intravitreal Bevacizumab for Macular Edema Secondary to Central Retinal Vein Occlusion**
Jose A. Roca
- 9:24-9:29 **Intravitreal Bevacizumab For Treatment Of Macular Edema In Central And Branch Retinal Vein Occlusion**
Ajay Dudani
- 9:29-9:34 **Ranibizumab (Lucentis) in Ischemic Central Retinal Vein Occlusion: Intermediate OCT and Visual Results from the RAVE trial**
Matthew S. Benz
- 9:34-9:38 **Discussion**
- 9:38-9:44 **Retinoblastoma Tumor Vascular Heterogeneity: A Model for Angiogenic Vacular Maturation and Implications for Vascular Targeting Therapy**
Timothy G. Murray
- 9:44-9:50 **Standard and High Resolution Echographic Features of Melanocytoma**
Amy C. Scheffler
- 9:50-10:00 **Discussion**
- 10:00-10:40 Break/Exhibits/Poster Session (Diabetic Retinopathy/Retinal Vascular Disease & Oncology/Macular Surgery) – Authors Present***
- 10:40-1:15pm Symposium VIII: Diabetic Retinopathy (Part 1)***
Presiding Officer: J. Fernando Arevalo
Chair: Athanasios Nikolakopoulos
Moderator: Robert L. Avery
- 10:40-10:45 **Clinical Detection of Diabetic Macular Edema (DME) Using the Automated Retinal Imaging System**
Antonio P. Ciardella
- 10:45-10:50 **Factors Influencing Utilization of a Telemedicine Diabetic Retinopathy Assessment Program in the Primary Care Setting**
Ingrid E. Zimmer-Galler
- 10:50-10:55 **Diurnal Variation in Retinal Thickening Measured by OCT**
Michel J. Shami
- 10:55-10:59 **Discussion**
- 10:59-11:04 **Subthreshold Micropulse Diode Laser Photocoagulation in the Treatment of Diabetic Clinically Significant Macular Edema**
Neelakshi Bhagat
- 11:04-11:09 **VEGF small interfering (si) RNA, Cand5, for Treatment of Diabetic Macular Edema (DME)**
Jonathan L. Prenner
- 11:09-11:14 **Three-Year Results of a Multicenter Clinical Trial of the Fluocinolone Acetonide Intravitreal Implant to Treat Diabetic Macular Edema**
Dean Elliott
- 11:14-11:19 **The I-vation Sustained Release Drug Delivery System and Intravitreal Implant**
Eugene de Juan, Jr.
- 11:19-11:22 **Discussion**
- 11:22-11:27 **The Effect of the Oral PKC β Inhibitor Ruboxistaurin on Visual Loss and Diabetic Macular Edema (DME)**
Ronald P. Danis

- 11:27-11:32 **The Effect of an Epiretinal Membrane on Intravitreal Triamcinolone Treatment for Diabetic Macular Edema**
Parin S. Gohel
- 11:32-11:37 **Predictive Factors for Visual Outcome after Intravitreal Triamcinolone Acetonide Injection for Diabetic Macular Edema**
Rishi Singh
- 11:37-11:40 **Discussion**
- 11:40-11:45 **Pegaptanib Sodium in Diabetic Retinopathy: Improvements in Diabetic Macular Edema, Retinal Neovascularization, and Severity of Diabetic Retinopathy**
Victor Hugo Gonzalez
- 11:45-11:50 **Optical Coherence Tomography Following Pegaptanib Therapy in Diabetics: a Bioanatomic Study of DME**
David R. Guyer
- 11:50-11:55 **Intravitreal injection versus systemic Bevacizumab (Avastin) Therapy for diabetic macular edema**
Murat Oncel
- 11:55-11:58 **Discussion**
- 11:58-12:03pm **Interim Results of the R.E.A.D. Study: Ranibizumab for Edema of the Macula in Diabetes**
Diana V. Do
- 12:03-12:08 **Primary Intravitreal Bevacizumab (Avastin) for the Treatment of Diabetic Macular Edema: Results of the Pan-American Collaborative Retina Study Group**
J. Fernando Arevalo
- 12:08-12:15 **Intravitreal Bevacizumab (Avastin) in the Treatment of Proliferative Diabetic Retinopathy**
Robert L. Avery
- 12:15-12:20 **Injection of Intravitreal Avastin before Vitrectomy Surgery in the treatment of Severe Proliferative Diabetic Retinopathy**
Stanislao Rizzo
- 12:20-12:23 **Discussion**
- 12:23-12:29 **A Simple Predictor of Vitrase® Efficacy for BCVA Improvement in Patients with Diabetes and Severe Vitreous Hemorrhage**
Abdhis R. Bhavsar
- 12:29-12:35 **Vitraxe for Vitreous Hemorrhage Revisited**
Michael A. Singer
- 12:35-12:38 **Discussion**
- 12:38-12:44 **25 Gauge Vitrectomy for Advanced Proliferative Diabetic Retinopathy: A Consecutive Case Series Including Complex Retinal Detachments**
Firas M. Rahhal
- 12:44-12:50 **Diabetic Traction Detachment Treated with Bimanual 25g Sutureless Surgery (Is silicon oil necessary?)**
Athanasios Nikolakopoulos
- 12:50-12:56 **Reoperation After Diabetic Vitrectomy: Rate, Indications, Visual Outcomes, and Complications in an Urban Academic Medical Center**
Julie Gasperini
- 12:56-1:02 **Posterior Juxtасcleral Injection of Triamcinolone Acetonide for Cases of Diabetic Macular Edema Unresponsive or Unamenable to Laser Treatment**
Franco M. Recchia
- 1:02-1:08 **Vitrectomy for Diabetic Macular Edema: Study Design and Preliminary Results of VIDE Study, an Italian Clinical Trial**
Barbara Parolini
- 1:08-1:15 **Discussion**

- 1:15-2:15 Lunch/Exhibits***
- 2:15-2:45 Symposium VIII: Diabetic Retinopathy (Part 2)***
- Panel Discussion**
Moderator: Harry W. Flynn, Jr.
Panelists: Tarek S. Hassan, Rodrigo Jorge, Frank HJ Koch, Brooks W. McCuen, II, Robert P. Murphy, Georgiy Stolyarenko
- 2:45-4:05 Symposium IX: Macular Surgery***
Presiding Officer: Claudio Azzolini
Chair: Fabio Patelli
Moderator: Keye L. Wong
- 2:45-2:51 **Posterior Retinal Detachment and Retinoschisis without a Macular Hole in Highly Myopic Eyes: Clinical findings and Management**
Hassan Mortada
- 2:51-2:57 **Myopic Traction Maculopathy: A Slowly Progressive and Treatable Disease**
Giacomo A. Panozzo
- 2:57-3:02 **Discussion**
- 3:02-3:08 **25 Gauge Macular Surgery: Results and Complications**
Fabio Patelli
- 3:08-3:14 **Surgical Treatment of Macular Pucker: Multicenter Clinical Trial**
Claudio Azzolini
- 3:14-3:20 **Outcomes of 25 gauge Transconjunctival Membrane Peeling Combined with Sutureless Phaco/IOL Surgery**
Jean-Paul Berrod
- 3:20-3:25 **Discussion**
- 3:25-3:31 **Combined Phacoemulsification and Vitrectomy for Macular Hole Repair**
Ioannis Theocharis
- 3:31-3:37 **Prospective Randomized Clinical Trial Comparing Face Down Position and Semi Seated Position after Surgery for Idiopathic Full-Thickness Macular Hole**
Alexandre Guillaubey
- 3:37-3:43 **ILM Peeling Prevents Late Reopening of Closed Macular Holes**
Thierry C. Verstraeten
- 3:43-3:49 **25 Gauge Transconjunctival Sutureless Vitrectomy (TSV) for Macular Holes (MH) repair: How can we resolve technique-related problems?**
Federica Genovesi-Ebert
- 3:49-3:55 **Results of Surgical Management of Senile Macular Holes by 25-Gauge Trans-Conjunctival Sutureless Vitrectomy Compared to Standard Vitrectomy Systems**
C. Christopher Brown
- 3:55-4:01 **Idiopathic Macular Holes Following Pars Plana Vitrectomy for Retinal Detachment**
Francesco Boscia
- 4:01- 4:05 **Discussion**
- 6:30-1:00am Film Festival Awards Ceremony/Gala Dinner/Nightclub***

7:30am-1:00pm **Registration**

8:00-9:23 Symposium X: Retinal Detachment*

Presiding Officer: Giampaolo Gini

Chair: Klaus Lucke

Moderator: Masoud Soheilian

8:00-8:06 **The Value and Cost-Effectiveness of Vitreoretinal Interventions**
Gary C. Brown

8:06-8:12 **Rhegmatogenous Retinal Detachment in Myopic Eyes after LASIK. Characteristics, Surgical Management and Functional Outcomes**
Anna Boixadera

8:12-8:18 **Use of 25-Gauge Pars Plana Vitrectomy Surgery for Primary Repair of Rhegmatogenous Retinal Detachments**
Amitabh Bharadwaj

8:18-8:20 **Discussion**

8:20-8:26 **Visual and Anatomic Outcomes of Pneumatic Retinopexy**
Daniel B. Roth

8:26-8:32 **Results of Pneumatic Retinopexy in Phakic Eyes - A Prospective Comparison of the Clinical Trial Group Inclusion Criteria and Extended Criteria**
Stephen M. Conti

8:32-8:35 **Discussion**

8:35-8:41 **Optic Pit Retinal Detachments – Attempt at a Unifying Theory**
Klaus Lucke

8:41-8:47 **Multiple Macular Retinal Detachments after Successful Buckle Surgery: Infrared, Autofluorescence, OCT and Microperimetric Features**
Francesco Faraldi

8:47-8:50 **Discussion**

8:50-8:56 **Incidence of Retinal Detachment after Macular Surgery: a Retrospective Study of 634 Cases**
Catherine Creuzot

8:56-9:02 **Cataract Surgery and Vitrectomy for Proliferative Vitreoretinopathy: Comparisons between Internal Tamponades and Lens Removal Techniques**
Marcio B. Nehemy

9:02-9:08 **Triamcinolone Acetonide in Silicone-filled Eyes as Adjunctive Treatment for Proliferative Vitreoretinopathy; A Randomized Clinical Trial**
Hamid Ahmadi

9:08-9:14 **Effect of Intraoperative 5-Fluorouracil and Low Molecular Weight Heparin on the Outcome in High-Risk Proliferative Vitreoretinopathy**
Guruprasad S. Ayachit

9:14-9:20 **Primary Vitrectomy in the Treatment of Retinal Detachment in Highly Myopic Eyes with Axial Length over 30mm**
Gregoire Minoyan

9:20-9:23 **Discussion**

9:23-10:00 Symposium XI: Trauma*

Presiding Officer: Giampaolo Gini

Chair: Klaus Lucke

Moderator: Masoud Soheilian

9:23-9:30 **Microbial Isolates and Sensitivities in Posterior-Segment Intraocular Foreign Body (IOFB) Injuries: A 10-year Review**
Samuel B. Barone

- 9:30-9:37 **Prophylaxis of Acute Post-Traumatic Bacterial Endophthalmitis with and without Intraocular Antibiotic Injection**
Masoud Soheilian
- 9:37-9:44 **Intraocular Foreign Body Removal at Walter Reed Army Medical Center During Operations Iraqi and Enduring Freedom**
Marcus Colyer
- 9:44-9:51 **Management of Traumatic Retinal Detachment Associated with Open Globe Injuries**
Giampaolo Gini
- 9:51-10:00 **Discussion**
- 10:00-10:40 Break/Exhibits/Poster Session (Pediatrics and Inflammatory Disease/Hereditary Retinal Disease & Genetics/Retinal Detachment/Trauma) – Authors Present***
- 10:40-12:15 Symposium XII: Pediatrics and Inflammatory Disease***
Presiding Officer: Harry W. Flynn, Jr.
Chair: Silvia Bopp
Moderator: Daniel F. Martin
- 10:40-10:46 **Screening for Retinopathy in the Pediatric Sickle Cell Patient Population**
Harmeet Gill
- 10:46-10:52 **PFV: Clinical Spectrum and Therapeutic Approach**
Silvia Bopp
- 10:52-10:57 **Discussion**
- 10:57-11:03 **Telemedicine Screening for Retinopathy of Prematurity: The Stanford Experience (SUNDROP)**
Steven R. Sanislo
- 11:03-11:09 **Safety and Efficacy of Intravitreal Bevacizumab for Retinopathy of Prematurity**
Hugo Quiroz-Mercado
- 11:09-11:15 **Anti-VEGF Therapy for Pediatric Retinopathies: Which Case is the Right Case?**
Kimberly A. Drenser
- 11:15-11:20 **Discussion**
- 11:20-11:26 **Endophthalmitis in the Newborn**
Kristen Hartley
- 11:26-11:32 **A 2006 Update on the Risks Associated with Intravitreal (IVT) Injection and Guidelines for Safe Administration**
Emmett T. Cunningham
- 11:32-11:38 **Acute-onset Endophthalmitis Following Clear Corneal Cataract Surgery (1996-2005): Clinical Features, Microbiology and Visual Outcomes**
Geeta Lalwani
- 11:38-11:44 **Early Onset Endophthalmitis Caused by Aspergillus Species Following Cataract Surgery**
Harry W. Flynn, Jr.
- 11:44-11:47 **Discussion**
- 11:47-11:53 **25-Gauge Vitrectomy Management of Severe Post-Cataract Surgery Endophthalmitis**
Flavio A. Rezende
- 11:53-11:59 **Complete and Early Vitrectomy for Eyes with Postoperative Endophthalmitis**
Ferenc Kuhn
- 11:59-12:05pm **In-office and Bedside Sutureless Vitrectomy for the Diagnosis of Uveitis**
Robert G. Josephberg
- 12:05-12:11 **Three-Year Results of a Multi-Center Clinical Trial of Fluocinolone Acetonide Intravitreal Implants to Treat Posterior Uveitis**
Daniel F. Martin

- 12:11-12:15 **Discussion**
- 12:15-12:40 Symposium XIII: Future Directions***
Presiding Officer: Harry W. Flynn, Jr.
Chair: Silvia Bopp
Moderator: Daniel F. Martin
- 12:15-12:20 **Sub-retinal Injection of Bevacizumab (Avastin) in Treating Neovascular Age-related Macular Degeneration, 25-gauge Approach**
Ehab El-Rayes
- 12:20-12:25 **Rationale for Genistein in the Prevention and Treatment of Diabetic Retinopathy**
Michael J. Cooney
- 12:25-12:30 **Application of Proteomic Analysis to Characterize the Molecular Pathways of the Vitreous and Retina in Health and Disease**
Bert M. Glaser
- 12:30-12:35 **Ultra-wide Angle Fluorescein Angiographic Evaluation of the Retinal Periphery in the Management of Retinal Vascular Diseases**
Steven D. Schwartz
- 12:35-12:42 **New Pharmacologic Treatments for Retinal Disease: A Venture Capital Perspective**
Gilbert H. Kliman
- 12:42-12:47 **Sterile Endophthalmitis Following Intravitreal Kenalog Injection: Recent Trends**
Alexander M. Eaton
- 12:47-12:52 **Discussion**
- 12:52-12:55 **Closing Remarks**

**This activity is an official Cannes Retina Festival event. No private events may be scheduled that conflict with this event.*